Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Mar 5;52(6):986–997. doi: 10.1093/rheumatology/ket018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2013. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — Mean change from baseline DAS28 (CRP) score in patients in the ACCOMPANY study (A) over 4 months for the ITT population [n = 49 in the s.c. abatacept monotherapy group, n = 51 in the s.c. abatacept combination (plus MTX) group] and (B) over 18 months for patients who entered the LTE (n = 43 in the monotherapy group, n = 47 in the combination group) (as-observed analysis). [15]. Copyright © 2012 by the American College of Rheumatology.

The ACCOMPANY study compared s.c. abatacept with or without MTX in patients with an inadequate response to ≥1 DMARD (MTX-naïve or MTX-IR). Mean (s.d.) baseline DAS28 (CRP) was 5.4 (1.4). Error bars represent 95% CI.